Study on the Efficacy of Low-Dose Mifepristone in the Treatment of Endometriosis

Abstract

Objective: To explore and analyze the efficacy of low-dose mifepristone in the treatment of endometriosis. Methods: 56 patients with endometriosis who were diagnosed and treated in the gynecology department of the People’s Hospital of Danyang between August 2020 to December 2022 were recruited and divided into the study group (n = 28) and control group (n = 28). The study group was treated with low-dose mifepristone, and the control group was treated with regular-dose mifepristone. The effective rate of medication, hormone levels, bone density, and adverse reactions were compared between the groups. Results: There was a statistically significant difference (P < 0.05) in the effective rates of medication between the study group and the control group. Before treatment, the hormone levels were not statistically significant between the groups (P > 0.05); after treatment, the hormone levels in the study group were significantly better than those in the control group (P < 0.05). Before treatment, there was no significant difference in bone mineral density between the groups (P > 0.05); after treatment, bone density in the study group was higher than that in the control group (P < 0.05). The incidence of adverse reactions in the study group was significantly lower than that in the control group (P <0.05). Conclusion: Low-dose mifepristone has a significant curative effect in the treatment of endometriosis, the hormone level and bone density are better, and there are few adverse drug reactions. This treatment is worthy of widespread promotion and application.